Kane Biotech Announces Private Placement Offering and Proposed Amendments to its Credit Facility
WINNIPEG, Manitoba, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 6,250,000 units of the Company (“Units”) at a price of $0.08 per Unit for gross proceeds of up to $500,000. Each Unit shall be comprised of one common share of the Company (a “Share”) and one-half of one Share purchase warrant (each whole warrant, a “Warrant”). Each full Warrant shall entitle the holder thereof to purchase one additional Share of the Company for a period of 18 months at an exercise price of $0.10 per Share.
- All securities issued in connection with the Offering will be subject to a hold period of four-months and one day in Canada.
- The Proposed Amended Credit Facility shall have an interest rate of 15% per annum.
- Under the terms of the Proposed Amended Credit Facility, Pivot and the third party guarantor of $1,000,000 of the Proposed Amended Credit Facility (the “Guarantor”), will each receive 2,500,000 compensation warrants (“Compensation Warrants”).
- The Proposed Amended Credit Facility is subject to the above-mentioned Offering being fully subscribed, the execution of definitive transaction documents and the receipt of all necessary approvals.